Overactive Bladder - Pipeline Review, H2 2011 by GlobalMarketsDirect

VIEWS: 11 PAGES: 101

More Info
									Overactive Bladder – Pipeline Review, H2 2011




              Overactive Bladder - Pipeline Review, H2 2011
                                                                                          Reference Code: GMDHC1474IDB

                                                                                          Publication Date: October 2011




Overactive Bladder – Pipeline Review, H2 2011                                                                    GMDHC1474IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                  Page(1)
Overactive Bladder – Pipeline Review, H2 2011



Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 7
      List of Figures .................................................................................................................................................................................................... 8
Introduction .............................................................................................................................................................................................................. 9
      Global Markets Direct Report Coverage ............................................................................................................................................................. 9
Overactive Bladder Overview ..................................................................................................................................................................................10
Therapeutics Development ......................................................................................................................................................................................11
      An Overview of Pipeline Products for Overactive Bladder .................................................................................................................................11
Overactive Bladder Therapeutics under Development by Companies ......................................................................................................................13
Overactive Bladder Therapeutics under Investigation by Universities/Institutes .......................................................................................................15
Late Stage Products ................................................................................................................................................................................................16
      Comparative Analysis .......................................................................................................................................................................................16
Mid Clinical Stage Products .....................................................................................................................................................................................17
      Comparative Analysis .......................................................................................................................................................................................17
Early Clinical Stage Products ..................................................................................................................................................................................18
      Comparative Analysis .......................................................................................................................................................................................18
Discovery and Pre-Clinical Stage Products..............................................................................................................................................................19
      Comparative Analysis .......................................................................................................................................................................................19
Overactive Bladder Therapeutics - Products under Development by Companies .....................................................................................................20
Overactive Bladder Therapeutics - Products under Investigation by Universities/Institutes ......................................................................................23
Companies Involved in Overactive Bladder Therapeutics Development ..................................................................................................................24
      Allergan, Inc. .....................................................................................................................................................................................................24
      Antares Pharma, Inc. ........................................................................................................................................................................................24
      Dainippon Sumitomo Pharma Co., Ltd. .............................................................................................................................................................25
      American Oriental Bioengineering, Inc. .............................................................................................................................................................25
      Astellas Pharma Inc. .........................................................................................................................................................................................26
      Auxilium Pharmaceuticals, Inc...........................................................................................................................................................................26
      Japan Tobacco Inc. ...........................................................................................................................................................................................27
      Kissei Pharmaceutical Co., Ltd. .........................................................................................................................................................................27
      Ono Pharmaceutical Co., Ltd. ...........................................................................................................................................................................28
      Pfizer Inc. ..........................................................................................................................................................................................................28
      Recordati S.p.A. ................................................................................................................................................................................................29
      Teva Pharmaceutical Industries Limited ............................................................................................................................................................29
      Merck KGaA......................................................................................................................................................................................................30
      Hisamitsu Pharmaceutical Co., Inc. ...................................................................................................................................................................30
      Urigen Pharmaceuticals, Inc..............................................................................................................................................................................31
      Plethora Solutions Holdings plc .........................................................................................................................................................................31
      KeyNeurotek Pharmaceuticals AG ....................................................................................................................................................................32
      Respiratorius AB ...............................................................................................................................................................................................32
      PharmEste ........................................................................................................................................................................................................33
      Hydra Biosciences, Inc. .....................................................................................................................................................................................33
      Mt Cook Pharma. Inc. .......................................................................................................................................................................................34
      Ion Channel Innovations, LLC ...........................................................................................................................................................................34
Overactive Bladder - Therapeutics Assessment ......................................................................................................................................................35
      Assessment by Monotherapy Products .............................................................................................................................................................35
      Assessment by Combination Products ..............................................................................................................................................................36
      Assessment by Route of Administration ............................................................................................................................................................37


Overactive Bladder – Pipeline Review, H2 2011                                                                                                                  GMDHC1474IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                                                 Page(2)
Overactive Bladder – Pipeline Review, H2 2011


      Assessment by Molecule Type ..........................................................................................................................................................................39
Drug Profiles ...........................................................................................................................................................................................................41
      SMP-986 - Drug Profile .....................................................................................................................................................................................41
            Product Description ....................................................................................................................................................................................41
            Mechanism of Action...................................................................................................................................................................................41
            R&D Progress .............................................................................................................................................................................................41
      ASP3652 - Drug Profile .....................................................................................................................................................................................42
            Product Description ....................................................................................................................................................................................42
            Mechanism of Action...................................................................................................................................................................................42
            R&D Progress .............................................................................................................................................................................................42
      YM905 - Drug Profile.........................................................................................................................................................................................43
            Product Description ....................................................................................................................................................................................43
            Mechanism of Action...................................................................................................................................................................................43
            R&D Progress .............................................................................................................................................................................................43
      Betanis - Drug Profile ........................................................................................................................................................................................44
            Product Description ....................................................................................................................................................................................44
            Mechanism of Action...................................................................................................................................................................................44
            R&D Progress .............................................................................................................................................................................................44
      UK-369003 - Drug Profile ..................................................................................................................................................................................45
            Product Description ....................................................................................................................................................................................45
            Mechanism of Action...................................................................................................................................................................................45
            R&D Progress .............................................................................................................................................................................................45
      AA4010 - Drug Profile .......................................................................................................................................................................................46
            Product Description ....................................................................................................................................................................................46
            Mechanism of Action...................................................................................................................................................................................46
            R&D Progress .............................................................................................................................................................................................46
      Anturol - Drug Profile.........................................................................................................................................................................................47
            Product Description ....................................................................................................................................................................................47
            Mechanism of Action...................................................................................................................................................................................47
            R&D Progress .............................................................................................................................................................................................47
      APT - Drug Profile .............................................................................................................................................................................................48
            Product Description ....................................................................................................................................................................................48
            Mechanism of Action...................................................................................................................................................................................48
            R&D Progress .............................................................................................................................................................................................48
      REC 0422 - Drug Profile....................................................................................................................................................................................49
            Product Description ....................................................................................................................................................................................49
            Mechanism of Action...................................................................................................................................................................................49
            R&D Progress .............................................................................................................................................................................................49
      REC 1819 - Drug Profile....................................................................................................................................................................................50
            Product Description ....................................................................................................................................................................................50
            Mechanism of Action...................................................................................................................................................................................50
            R&D Progress .............................................................................................................................................................................................50
      PSD506 - Drug Profile.......................................................................................................................................................................................51
            Product Description ....................................................................................................................................................................................51
            Mechanism of Action...................................................................................................................................................................................51
            R&D Progress .............................................................................................................................................................................................51
      URG302 - Drug Profile ......................................................................................................................................................................................53
            Product Description ....................................................................................................................................................................................53




Overactive Bladder – Pipeline Review, H2 2011                                                                                                                GMDHC1474IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                                              Page(3)
Overactive Bladder – Pipeline Review, H2 2011


          Mechanism of Action...................................................................................................................................................................................53
          R&D Progress .............................................................................................................................................................................................53
     XEN-D0501 - Drug Profile .................................................................................................................................................................................54
          Product Description ....................................................................................................................................................................................54
          Mechanism of Action...................................................................................................................................................................................54
          R&D Progress .............................................................................................................................................................................................54
     JTS-653 - Drug Profile.......................................................................................................................................................................................55
          Product Description ....................................................................................................................................................................................55
          Mechanism of Action...................................................................................................................................................................................55
          R&D Progress .............................................................................................................................................................................................55
     KN203 - Drug Profile .........................................................................................................................................................................................56
          Product Description ....................................................................................................................................................................................56
          Mechanism of Action...................................................................................................................................................................................56
          R&D Progress .............................................................................................................................................................................................56
     MK-4618 - Drug Profile......................................................................................................................................................................................57
          Product Description ....................................................................................................................................................................................57
          Mechanism of Action...................................................................................................................................................................................57
          R&D Progress .............................................................................................................................................................................................57
     ONO-8539 - Drug Profile ...................................................................................................................................................................................58
          Product Description ....................................................................................................................................................................................58
          Mechanism of Action...................................................................................................................................................................................58
          R&D Progress .............................................................................................................................................................................................58
     ONO-8539 - Drug Profile ...................................................................................................................................................................................59
          Product Description ....................................................................................................................................................................................59
          Mechanism of Action...................................................................................................................................................................................59
          R&D Progress .............................................................................................................................................................................................59
     KUC-7483 - Drug Profile ...................................................................................................................................................................................60
          Product Description ....................................................................................................................................................................................60
          Mechanism o
								
To top